B02BD06 • coagulation factor VIII and von Willebrand factor • Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors
The combination of coagulation factor VIII and von Willebrand factor is used in the treatment of hemophilia A and von Willebrand disease, two conditions involving blood clotting disorders. Factor VIII helps form the clot, while von Willebrand factor stabilizes factor VIII and facilitates platelet adhesion at the site of injury.
This combination is administered intravenously under medical supervision, with the dose adjusted according to the severity of the deficiency and the type of bleeding. Treatment can be given prophylactically or as needed, especially before surgeries or in case of trauma.
Side effects may include allergic reactions, fever, headaches, or, rarely, the development of antibodies that can reduce the effectiveness of the treatment. Careful monitoring of the patient is essential to quickly detect any adverse reactions and adjust the treatment if necessary.
Therapy with factor VIII and von Willebrand factor has significantly improved the quality of life for patients with bleeding disorders. Following medical advice and being informed about possible risks contribute to safe and effective treatment.
Substance: coagulation factor VIII and von Willebrand factor
Date of last drug list: 10-04-2026
Commercial code: W62887001
Concentration: 500UI / 375UI
Pharmaceutical form: powder+solvent for injection
Quantity: 1
Product type: original
Price: 787.90 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: TAKEDA MANUFACTURING AUSTRIA AG - AUSTRIA
Holder: BAXALTA INNOVATIONS GMBH - AUSTRIA
Number: 5419/2013/01
Shelf life: 2 years-after packing for marketing; after reconstitution-it is used immediately